Mumbai, India, March 21, 2026: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced the launch of its semaglutide injection under the brand names Noveltreat and Sematrinity in India, in all strengths. Noveltreat is indicated for chronic weight management in adults as an adjunct to a reduced calorie diet & increased physical activity and is available in five dose strengths – 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and
2.4 mg/0.75 mL. Sematrinity is indicated for treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet & exercise and is available in two dose strengths – 2 mg/1.5 mL and 4 mg/3 mL. Priced significantly lower than the innovator brand, weekly therapy costs, from initiation to the highest dose, range from approximately ₹900 to ₹2,000 for Noveltreat and ₹750 to
₹1,300 for Sematrinity, supporting greater affordability.
Commenting on the launch, Kirti Ganorkar, Managing Director, Sun Pharmaceutical Industries Ltd, said, “With the launch of Noveltreat and Sematrinity, our endeavour is to provide a high-quality, affordable therapy to a wider patient community in India. We are offering a comprehensive range, backed by our decades of expertise in manufacturing complex medicines. To further support patients, we are also introducing a holistic patient support program intended to guide them throughout their treatment journey”.
Noveltreat’s prefilled pen uses a concealed needle to help ease injection fear and improve both handling safety and dosing accuracy. Sematrinity comes in a multi-dose pen format that offers flexible dosing, with a smooth dialer that enables accurate dose delivery. The easy-to-use, pre-filled pens, developed by leading global pharmaceutical device suppliers, are manufactured in Europe.
